Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Account Payables (2021 - 2025)

Historic Change in Account Payables for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$33000.0.

  • Amylyx Pharmaceuticals' Change in Account Payables rose 9905.36% to -$33000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 13737.9%. This contributed to the annual value of -$19.1 million for FY2024, which is 22027.45% down from last year.
  • According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Change in Account Payables is -$33000.0, which was up 9905.36% from -$1.5 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Change in Account Payables' 5-year high stood at $15.8 million during Q4 2023, with a 5-year trough of -$18.4 million in Q3 2023.
  • Moreover, its 5-year median value for Change in Account Payables was -$33000.0 (2025), whereas its average is -$20578.9.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Change in Account Payables soared by 273615.82% in 2022 and then crashed by 157057.22% in 2023.
  • Amylyx Pharmaceuticals' Change in Account Payables (Quarter) stood at $1.4 million in 2021, then plummeted by 157.72% to -$800000.0 in 2022, then surged by 2077.5% to $15.8 million in 2023, then crashed by 90.7% to $1.5 million in 2024, then crashed by 102.24% to -$33000.0 in 2025.
  • Its Change in Account Payables stands at -$33000.0 for Q3 2025, versus -$1.5 million for Q2 2025 and $1.9 million for Q1 2025.